PNU-181731 explained

PNU-181731 is a drug which acts as an agonist at serotonin 5-HT2 receptors,[1] [2] with strongest binding affinity for the 5-HT2C subtype at 4.8nM, and weaker 5-HT2A affinity of 18nM. It has anxiolytic effects in animal studies with around one tenth the potency of alprazolam and no significant ataxia or other side effects noted.[3]

See also

Notes and References

  1. 2,3,4,5-Tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds. ]. Ennis ME, et al. . Pharmacia and Upjohn Co Inc. US . 6734301 . March 14, 2000 . May 11, 2004 .
  2. Fused heterocyclic compound and use thereof. . Shirai J, et al. . Takeda Pharmaceutical Co Ltd . US . 8158617 . May 16, 2006 . April 17, 2012 .
  3. Ennis MD, Hoffman RL, Ghazal NB, Olson RM, Knauer CS, Chio CL, Hyslop DK, Campbell JE, Fitzgerald LW, Nichols NF, Svensson KA, McCall RB, Haber CL, Kagey ML, Dinh DM . 6 . 2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists . Bioorganic & Medicinal Chemistry Letters . 13 . 14 . 2369–72 . July 2003 . 12824036 . 10.1016/S0960-894X(03)00403-7 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "PNU-181731".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.